Stocks Health care CURX
NASDAQ · Health careCuranex Pharmaceuticals Inc (CURX)
It posted a net loss of $10.5M. At June 30, 2026 it held $2.9M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
Key facts about Curanex Pharmaceuticals Inc
- Net worth
- Curanex Pharmaceuticals Inc has a market value (market cap) of $177.5M at the latest share price, and shareholders' equity of $4.8M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $10.5M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 14, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Curanex Pharmaceuticals Inc's next report is expected around November 16, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Curanex Pharmaceuticals Inc does
Curanex Pharmaceuticals Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker CURX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$4.2M | -$0.17 | n/a |
| 2025 | n/a | -$361.5K | -$0.03 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Curanex Pharmaceuticals Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 4, 2026Other event 8-K
- August 17, 2026
- August 14, 2026
- July 21, 2026
- June 29, 2026Form DEF 14C filing DEF 14C
- June 18, 2026Form PRE 14C filing PRE 14C
- May 14, 2026
- May 14, 2026
- May 7, 2026Other event 8-K
- April 2, 2026
Insider trades
What the people running Curanex Pharmaceuticals Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Questions about CURX
What does Curanex Pharmaceuticals Inc do?
Curanex Pharmaceuticals Inc is a company in the Health care sector, listed on NASDAQ as CURX. Its shares trade on NASDAQ under the ticker CURX.
What is Curanex Pharmaceuticals Inc's net worth?
Curanex Pharmaceuticals Inc has a market value (market cap) of $177.5M at the latest share price, and shareholders' equity of $4.8M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Curanex Pharmaceuticals Inc profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $10.5M.
When did Curanex Pharmaceuticals Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the other event from September 4, 2026.
When is Curanex Pharmaceuticals Inc's next earnings report?
Curanex Pharmaceuticals Inc's next report is expected around November 16, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare CURX with
Follow CURX
Get an email when Curanex Pharmaceuticals Inc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Curanex Pharmaceuticals Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.